Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Head & Neck 5Endocrine 5

Conditions

Neuroendocrine Tumors 11Adrenocortical Carcinoma 7Thyroid Carcinoma, Anaplastic 5Carcinoma, Neuroendocrine 4Thyroid Neoplasms 3Adrenal Cortex Neoplasms 3Ovarian Neoplasms 2Neoplasm Metastasis 2Carcinoma, Small Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Penile Neoplasms 1Pathologic Processes 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Paraganglioma 1Neoplasms, Unknown Primary 1Neoplasms, Germ Cell and Embryonal 1Multiple Myeloma 1

Interventions

Paclitaxel 10trametinib 9dabrafenib 9pembrolizumab 5lenvatinib 5fosbretabulin 4Sorafenib 4Radiotherapy, Intensity-Modulated 4Doxorubicin 4Radiotherapy 3Cisplatin 3pazopanib 2efatutazone 2combretastatin 2cobimetinib 2cemiplimab 2atezolizumab 2aldesleukin 2Vemurafenib 2Trastuzumab 2Taxes 2Nivolumab 2Gefitinib 2Filgrastim 2Everolimus 2Docetaxel 2Carboplatin 2Bevacizumab 2zimberelimab 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × pembrolizumab × Endocrine × Clear all
NCT04675710 2026-02-19

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT04171622 2026-02-17

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
25 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT06374602 2025-09-05

Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer

Saint Petersburg State University, Russia

Phase 2 Recruiting
20 enrolled
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02688608 2022-02-10

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

Stanford University

Phase 2 Completed
6 enrolled 10 charts
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT03211117 2020-03-25

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

Mayo Clinic

Phase 2 Completed
3 enrolled 7 charts
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡